Table 1 Characteristics of the AML patients.

From: Caspase-2 is a mediator of apoptotic signaling in response to gemtuzumab ozogamicin in acute myeloid leukemia

 

Patient

FAB

Cytogenetic analysis

CR (Days)

Short CR (< 6months)

#1

M2

No metaphases

79

#2

M5A

46, XY, del (11)(q23) [25], 46, XY[10]

21

#3

M1

46,XX [32]

12

#4

M5B

46, XX [29]

38

#5

M1

ND

26

#6

M2

46, XX [43]

106

#7

M1

46, XX [35]

113

#8

M1

No metaphases

51

#9

M2

46, XX

39

#10

M1

46, XX [4]

109

#11

M1

ND

56

Long CR (> 6months)

#12

M4

46, XY, inv (16)(p13q22)

304

#13

M1

ND

235

#14

M1

del (7q)(q22) [6]

588

#15

M1

46, XX [29]

231

#16

M1

t(8:21)(q22:q22), y- [21]

1182

#17

M2

46, XX [22]

271

#18

M1

46, XX, Ph + /46, XX, Ph + , -18, +mar/46, XX [29]

190

#19

M2

47 [1]

714

#20

M5B

ND

332

#21

M5B

ND

893

#22

M2

t(8:21)(q22:q22) [3] / 46, XY [9]

3701

  1. FAB French–American–British classification of acute myeloid leukemia, CR complete remission duration, ND not determined (no sample analysed), No metaphases – no cytogenetic analysis of the sample possible; [x] – number of metaphases.
Back to article page